Following our in vitro optimization, we demonstrate here for the first time that systemic delivery of the optimal PMO PACS4 ameliorated DUX4-mediated pathology in an FSHD-like mouse model. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.